임상시험용 CRO 시장 : 세계 예측(2026-2032년)

The CRO in Clinical Trials Market is projected to grow by USD 48.33 billion at a CAGR of 6.93% by 2032.

Clinical Research Outsourcing Is Becoming a Strategic Operating Model

Contract research organizations (CROs) support clinical development through services such as protocol design, site management, patient recruitment, data management, biostatistics, safety monitoring, and regulatory assistance. Their role is expanding as sponsors seek specialized capabilities, flexible resourcing, broader geographic reach, and stronger execution discipline across increasingly complex trials.

The sector is shaped by rising protocol complexity, decentralized and hybrid trial models, greater scrutiny of data quality, and demand for faster evidence generation. Sponsors are increasingly evaluating CROs not only as service providers, but also as partners capable of coordinating technology, investigators, patients, regulators, and multiple development functions.

Decentralization, Patient Centricity, and Evidence Complexity Are Reshaping Delivery

Clinical trial operations are shifting from predominantly site-centered models toward hybrid approaches that combine conventional visits with remote assessments, connected devices, telehealth, home nursing, and digital patient engagement. This evolution can improve convenience and broaden participation, but it also requires careful management of data interoperability, participant support, investigator oversight, and local compliance obligations.

At the same time, trials are incorporating more biomarkers, real-world data, adaptive designs, specialized endpoints, and complex patient populations. These changes increase the need for integrated operational planning, strong vendor governance, risk-based quality management, and consistent processes across countries and sites. CROs with multidisciplinary expertise and reliable execution frameworks are better positioned to address these requirements.

Artificial Intelligence Is Strengthening Trial Planning, Execution, and Oversight

Artificial intelligence is being applied across clinical research to identify suitable investigators and sites, improve feasibility assessments, support patient-trial matching, automate document workflows, detect data anomalies, and assist medical coding and safety case processing. When appropriately validated, these tools can reduce repetitive work and help teams prioritize operational risks earlier.

The cumulative effect depends on data quality, model transparency, human review, cybersecurity, and compliance with applicable privacy and clinical research requirements. AI does not remove the need for experienced clinical, statistical, medical, and regulatory judgment. Leaders should establish governance covering validation, change control, bias monitoring, auditability, access permissions, and clear accountability for decisions influenced by automated systems.

Regional Execution Models Reflect Distinct Regulatory and Infrastructure Conditions

North America benefits from mature clinical research infrastructure, experienced investigators, advanced data capabilities, and substantial sponsor activity, while operational teams must manage demanding regulatory, privacy, and diversity expectations. Europe offers deep scientific expertise and broad access to specialized investigators, but cross-border studies require careful coordination of national requirements, ethics processes, language, and data protection.

Asia-Pacific combines large and diverse patient populations with growing research capabilities and expanding digital infrastructure. Execution depends on country-specific regulatory navigation, site readiness, translation, and quality consistency. Latin America can provide access to relevant patient populations and experienced sites, while sponsors must address logistics, regulatory variation, and continuity planning. The Middle East is developing specialized research capacity and digital health infrastructure, with relationship management and regulatory alignment remaining important. Africa offers opportunities to broaden participation and address diseases underrepresented in global research; sustainable site development, training, ethics capacity, and supply-chain reliability are essential.

Economic and Security Groupings Influence Collaboration and Trial Resilience

ASEAN markets offer expanding clinical research opportunities but require coordinated approaches to differing regulatory systems, languages, health infrastructures, and site capabilities. BRICS economies provide substantial scientific and patient resources, although operational planning must account for varied approval pathways, data rules, payment structures, and geopolitical conditions.

The European Union supports multinational research through shared frameworks while retaining important national implementation differences. G7 countries generally provide strong research infrastructure, sophisticated regulation, and advanced digital capabilities, alongside high expectations for evidence quality and participant protection. GCC states are investing in healthcare modernization and research capacity, making local partnerships, workforce development, and culturally appropriate engagement important. NATO countries span mature and emerging research environments; resilience planning should consider cross-border data, logistics, cybersecurity, and continuity of operations.

Country-Level Conditions Require Tailored Trial Strategies

Australia offers experienced investigators and a well-established research environment, while Brazil and Mexico provide important patient access and regional research capacity that require attentive regulatory, logistical, and site-management planning. Canada combines strong academic capabilities with geographically dispersed populations, making centralized coordination and participant access important. China and India offer extensive clinical resources and specialized expertise, with country-specific regulatory, data, quality, and partnership requirements requiring careful attention.

France, Germany, Italy, and Spain contribute substantial European investigator networks and therapeutic expertise; successful execution depends on aligning national processes, ethics requirements, contracting, language, and site workflows. Japan and South Korea provide advanced healthcare and technology ecosystems, with high expectations for protocol quality, regulatory compliance, and localized engagement. Russia presents heightened operational, regulatory, geopolitical, and continuity considerations. The United Kingdom remains a major research environment with strong scientific capabilities, while the United States offers broad investigator depth and advanced trial infrastructure alongside complex regulatory, privacy, reimbursement, and participant-diversity requirements.

Leaders Should Build Resilient, Patient-Centered, and Data-Enabled Partnerships

Industry leaders should segment CRO partners by therapeutic expertise, geographic capabilities, technology maturity, quality performance, and ability to integrate multiple functions. Selection criteria should include transparent delivery metrics, investigator relationships, patient-recruitment evidence, inspection readiness, subcontractor controls, cybersecurity, and contingency planning-not only price or historical scale.

Sponsors should adopt interoperable data standards, risk-based oversight, and early feasibility work that tests recruitment assumptions and site capacity before commitments are finalized. They should also establish clear AI governance, maintain human accountability, invest in investigator and patient support, and design regional operating models that reflect local regulation and healthcare access. Continuous performance reviews tied to quality, cycle time, participant experience, data completeness, and issue resolution can improve partnership outcomes.

Methodology Combines Structured Market Review With Operational and Geographic Analysis

This executive summary is based on a structured assessment of CRO-supported clinical trial activities, including development services, operational delivery, technology adoption, regulatory considerations, patient engagement, and quality management. The analysis organizes insights by transformation theme and evaluates how regional, economic-group, and country conditions affect trial planning and execution.

Evidence should be interpreted through verified sources such as regulatory publications, clinical-trial registries, peer-reviewed research, public health and trade databases, sponsor disclosures, investigator and site information, and documented industry practices. Findings are synthesized qualitatively to identify strategic implications while avoiding unsupported estimates, forecasts, market shares, or claims that cannot be independently substantiated.

Execution Excellence Will Define the Next Phase of Clinical Trial Outsourcing

CROs are increasingly central to how sponsors manage clinical complexity, access specialized capabilities, and extend trial reach across diverse healthcare environments. Competitive advantage will depend on dependable execution, patient-centered design, integrated data, regulatory fluency, and the ability to manage technology and partners responsibly.

The strongest operating models will balance global consistency with local adaptation. Sponsors that treat outsourcing as a governed strategic partnership-supported by measurable quality standards, resilient supply and site networks, transparent data practices, and accountable AI use-will be better equipped to conduct credible, inclusive, and operationally efficient clinical trials.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. CRO in Clinical Trials Market, by Service Type

• 7.1. Introduction
• 7.2. Biostatistics
• 7.3. Clinical Trial Management
  • 7.3.1. Phase I
  • 7.3.2. Phase II
  • 7.3.3. Phase III
  • 7.3.4. Phase IV
• 7.4. Data Management
  • 7.4.1. Clinical Data Warehouse
  • 7.4.2. eClinical Solutions
  • 7.4.3. Electronic Data Capture
• 7.5. Laboratory Services
  • 7.5.1. Central Laboratory
  • 7.5.2. Integrated Laboratory Services
• 7.6. Medical Writing
• 7.7. Patient Recruitment
• 7.8. Pharmacovigilance
• 7.9. Regulatory Affairs
• 7.10. Site Management

8. CRO in Clinical Trials Market, by Therapeutic Area

• 8.1. Introduction
• 8.2. Cardiovascular
  • 8.2.1. Coronary Artery Disease
  • 8.2.2. Heart Failure
• 8.3. Endocrinology
• 8.4. Infectious Diseases
  • 8.4.1. Bacterial Infections
  • 8.4.2. Viral Infections
• 8.5. Neurology
  • 8.5.1. Central Nervous System Disorders
  • 8.5.2. Neurodegenerative Disorders
• 8.6. Oncology
  • 8.6.1. Hematological Cancers
  • 8.6.2. Solid Tumors
• 8.7. Respiratory

9. CRO in Clinical Trials Market, by Phase

• 9.1. Introduction
• 9.2. Phase I
• 9.3. Phase II
• 9.4. Phase III
• 9.5. Phase IV

10. CRO in Clinical Trials Market, by Trial Design

• 10.1. Introduction
• 10.2. Interventional
• 10.3. Observational

11. CRO in Clinical Trials Market, by End User

• 11.1. Introduction
• 11.2. Biotechnology Companies
• 11.3. Medical Device Companies
• 11.4. Pharmaceutical Companies

12. CRO in Clinical Trials Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. CRO in Clinical Trials Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. CRO in Clinical Trials Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Charles River Laboratories International Inc.
• 16.2. CMIC Holdings Co. Ltd.
• 16.3. Ergomed plc
• 16.4. Fortrea Holdings Inc.
• 16.5. ICON plc
• 16.6. IQVIA Holdings Inc.
• 16.7. Jubilant Pharmova Limited
• 16.8. Laboratory Corporation of America Holdings
• 16.9. Medpace Holdings Inc.
• 16.10. Novotech Pty Ltd.
• 16.11. Parexel International Corporation
• 16.12. PSI CRO AG
• 16.13. Syneos Health Inc.
• 16.14. TFS International AB
• 16.15. Thermo Fisher Scientific Inc.
• 16.16. Veeda Clinical Research Pvt. Ltd.
• 16.17. Worldwide Clinical Trials Inc.
• 16.18. WuXi AppTec Co. Ltd.

17. Key Experts